6th World Congress on

MEDICINAL CHEMISTRY AND DRUG DESIGN

June 07-08, 2017 Milan, Italy

CZ415, a highly selective mTOR inhibitor showing *in vivo* efficacy in a collagen induced arthritis (CIA) model

Giovanna Bergamini GSK Company, Germany

CZ415, a potent ATP-competitive mTOR inhibitor with unprecedented selectivity over other kinases will be presented here. It's *in vivo* pharmacokinetic profile will be reported, in addition to a comprehensive characterization of its *in vitro* activities and ADME data. The suitability of this inhibitor for studying *in vivo* mTOR biology is shown by the inhibition of target-dependent phosphorylation signaling observed in a mechanistic mouse model following oral administration. The compound reported here is the first ATP-competitive mTOR inhibitor described to show efficacy in a semi-therapeutic collagen induced arthritis (CIA) mouse model

Biography

Giovanna Bergamini has completed her PhD in Virology at the University of Bologna. She was a Post-doctoral Researcher at the European Molecular Biology Laboratory in Heidelberg, Germany. At Cellzome in Heidelberg, she leads Drug Discovery Programs in the Immuno-inflammation Therapeutic area. As a Director of Discovery Biology following acquisition of Cellzome from GSK, she oversees numerous activities on the investigation of drug mode of action across the GSK portfolio. She has published more than 20 papers in high impact journals.

giovanna.2.bergamini@gsk.com

Notes: